Establishment and Characterization of Meningioma Patient-derived Organoids

Completed

• Conditions: Meningioma

• Registration Number: NCT04478877
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.

Detailed Description

Aims and Hypothesis to be tested:

The investigators hypothesized that the derived organoid should have a similar morphological and genetic mutation signatures to the patient primary tissue.

Study period: 1 year for patient recruitment and organoid generation from patient tumor

Study population: 30

Study samples:

Patient's meningioma tumor sample are collected from patients with surgical needs. Sample collected are used for organoid culture. Morphological and genetic characteristics will be compared between the patient tumor sample and the corresponding derived organoids

Primary outcome measures:

Whole exome sequencing data of patient tumor tissue and patients-derived organoids

Study Timeline

• Study Start: 2020-05-23
• Study First Submitted: 2020-07-16
• Study First Submitted QC: 2020-07-16
• Study First Posted: 2020-07-21
• Primary Completion: 2023-08-31
• Study Completion: 2023-08-31
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-06
• Last Update Posted: 2023-09-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Adult patients (aged >18 years) with meningioma
2. Admission into Prince Wales hospitals neurosurgical services
3. Patients with surgical needs of meningioma removal

Exclusion Criteria

1. Patients (or next-of-kin as appropriate) refuse to participate into the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Whole exome sequencing data	7 days	DNA extracted from patient tumor tissue and patients-derived organoids will be perform whole exome sequencing for genetic characterization.

Secondary Outcome Measures

Name	Time	Method
Immunostaining	7 days	H\&E staining and meningioma markers immunostaining

Trial Locations

Locations (1)

Department of Surgery, The Chinese University of Hong Kong; 🇭🇰 Hong Kong, Hong Kong